Document is current
Any future updates will be listed below
-
Authors
Hong, Huangming
Chen, Zegeng https://orcid.org/0000-0003-4755-6711
Cui, Jie
Zhang, Qingyuan
Li, Ping
Tao, Rong
Huang, He
Wang, Binghua
Li, Wuping
Wu, Hui
Wei, Jin
Su, Liping
Zhang, Zhihua
Zhong, Mingxing
Wang, Huaqing
Wang, Cong
Zhou, Hui
Wang, Jishi
Dong, Min
Lin, Tongyu
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05400876 at ClinicalTrials.govnct05400876 at ClinicalTrials.govDocuments that mention this clinical trial
Anti-TIM-3 antibody TQB2618 in combination with penpulimab in relapsed or refractory classic Hodgkin lymphoma previously treated with PD-1/PD-L1 therapy: a multicenter, open-label, single-arm, phase Ib clinical trial
https://doi.org/10.1136/jitc-2026-014968
Documents that mention this clinical trial
Anti-TIM-3 antibody TQB2618 in combination with penpulimab in relapsed or refractory classic Hodgkin lymphoma previously treated with PD-1/PD-L1 therapy: a multicenter, open-label, single-arm, phase Ib clinical trial
https://doi.org/10.1136/jitc-2026-014968
-
Funding
Funding for this research was provided by:
Cancer Innovative Research Program of Sun Yat-sen University Cancer Center (CIRP-SYSUCC-0022)
National Natural Science Foundation of China (82270198)
National Natural Science Foundation of China (82470237)
National Natural Science Foundation of China (82500236)
National Natural Science Foundation of China (82570232)
National Natural Science Foundation of China (U24A20679)
- License Information
